Astrazeneca Shs Sponsored American Deposit Receipt Repr 1 Sh $63.49

down -0.04


17/4/2014 06:40 PM  |  NYSE : AZN  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get AZN Trend Analysis - it has outperformed the S&P 500 by 5%

Partner Headlines

  1. Sunday Times Reports Pfizer Considering $100B Offer for AstraZeneca

    Benzinga
  2. Myriad, Tata Motors Among RS Leaders In Correction

    IBD
  3. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest ...

    Benzinga
  4. Abbott Capturing Incremental Market Share

    GuruFocus
  5. Abbvie's Humira Continues to be a Powerful Catalyst for Growth

    GuruFocus
  6. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  7. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  8. AstraZeneca hurt by generics

    IBD
  9. AstraZeneca Q4 Mixed, But Alzheimer's Drug Advances

    IBD
  10. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  11. Market Wrap For January 22: Earnings Season Continues To Come In Mixed

    Benzinga
  12. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  13. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is

    GuruFocus
  14. Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff

    Benzinga
  15. Stocks Hitting 52-Week Highs

    Benzinga
  16. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
  17. ObamaCare = Drug Maker Assistance Act

    YCharts
  18. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  19. Benzinga's Top Downgrades

    Benzinga
  20. AstraZeneca in $4 bil-plus buy

    IBD
  21. Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus

    IBD
  22. Market Wrap For December 18: Markets Flat During Day One Post Fed Taper

    Benzinga
  23. Bristol-Myers Dumping Disaster Onto AstraZeneca?

    YCharts
  24. AstraZeneca Buys Out Bristol-Myers' Diabetes Business

    IBD
  25. AstraZeneca to Buy Bristol's Stake in Joint Venture

    FoxBusiness
  26. Cubist drug passes 2nd test

    IBD
  27. Suppose Medicare Negotiated Like This?

    YCharts
  28. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
  29. Cubist Antibiotic Passes Second Test; FDA Filing Next

    IBD
  30. Bristol, AstraZeneca pull drug

    IBD
  31. Genpact, AstraZeneca Extend Finance and Accounting Services Agreement

    Benzinga
  32. Health Care Heartiest, Gold Funds All Red In November

    IBD
  33. Icahn stake boosts Hologic

    IBD
  34. Icahn's Buy Into Hologic Welcomed By Wall Street

    IBD
  35. Horizon to Acquire US Rights for VIMOVO from Pozen

    Benzinga
  36. Benzinga's Top Upgrades

    Benzinga
  37. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  38. Statin Rules Change: Does Pharma Have A Winner?

    YCharts
  39. List: $34B In Pharma Sales Lose Patent in 2014

    YCharts
  40. Where J&J $2.2B Settlement Fits Among Biggest

    YCharts
  41. Two Mega-Launches in Pharma Industry

    YCharts
  42. AstraZeneca Appoints New CFO as Profit Falls

    FoxBusiness
  43. Benzinga's Top Upgrades

    Benzinga
  44. Acacia Subsidiary Enters into Settlement Agreement with AstraZeneca

    Benzinga
  45. AstraZeneca Reports New Safety Data for Naloxegol, Says Most Naloxegol-Emergent ...

    Benzinga
  46. How Much Do Analysts Hype Drug Launches?

    YCharts
  47. Profits Are Good, Cures Are Better: The Pharmaceutical Industry

    GuruFocus
  48. Amgen, AstraZeneca Highlight Brodalumab Data to be Presented at EADV

    Benzinga
  49. 4 High-Yielding Stocks with Safe Haven Characteristics and 9 Additional ...

    GuruFocus
  50. Pharma's Cheerleaders: Drug Reps' Jobs At Risk

    YCharts
Trading Center